Manufacturing Capabilites

Manufacturing Capabilities PDF 180KB

Primary Sites

Site-specific centres of production excellence
Large-scale capabilities leading to COGS benefits
Ensures uniform quality globally
Specialist capabilities and skills
Provide overall strategic advantage for Group
Globally accredited

SOUTH AFRICA: One of our flagship manufacturing sites in Port Elizabeth, South Africa

API Facilities

Biological capabilities including heparin where Aspen has become a significant global player
Capabilities include biochemicals, peptides, steroid/hormones, high potency products and other chemicals
Manufacturing capabilities enable control and access over niche pipeline opportunites
Provides vertical integration advantage for Group

FRANCE: Our Notre Dame de Bondeville specialist sterile manufacturing site in Rouen, France

Regional Facilities

Supply local/regional needs across diverse territories

HEAD OFFICE: Our Head Office in Durban, South Africa

FDF Capacity & Capability

FY 2000

Tablets only

FY 2013

Predominantly solids with some Speciality

FY 2017

Dominant sterile platform with Speciality & Solids

FY 2022

Further evolution to Sterile Manufacturing

API Capacity & Capability

Total Capacity 200 KvH

Capabilites
Anaesthetics
Muscle relaxants
Narcotics
Analgesics
Antineoplastics
Bronchodilators

FY 2013

FY 2017

Total Capacity 200 KvH

Added Capabilites
High Potency & Cytotoxics
Steroids/Alkaloids/Heterocyclics
Conugated & Esterified estrogens
Peptides
Hormonal & General intermediates
Biochemicals - Heparin & Danaparoid Gonadotrpins

NDB:

Purification of Fondaparinux
Conversion of heparin to Nadroparin

Broader geographic diversity
Enhanced capabilities
Five fold capacity increase